Previous 10 | Next 10 |
Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the publication of...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Bioprocessi...
Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announces that it is today publishin...
Milestone achieved for SENS-501 gene therapy program with Clinical Trial Application approval in Europe (France as first country) Communication on first patient expected in H2 2024 GJB2 gene therapy program advancing towards Clinical Trial Applications filing expected ...
Presence of SENS-401 in the perilymph is confirmed in 100% of the patients sampled following cochlear implantation at levels compatible with potential therapeutic efficacy Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology comp...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, will publish its 2023 financial results on March 14,...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Leerink Par...
Support from existing investors Redmile Group, Invus and Sofinnova Partners Participation from leading US Healthcare Specialists funds including Aquilo Capital, as well as two large investment management firms Financing will enable the Company to extend its cash runway thr...
2024-02-01 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the recruitment of the last patient ...
News, Short Squeeze, Breakout and More Instantly...
RiverNorth Flexible Municipal Income Fund Inc. Company Name:
RFM Stock Symbol:
NYSE Market:
RiverNorth Flexible Municipal Income Fund Inc. Website:
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Ms Laurene Danon ...
2024-06-24 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that promising new data and analysis...